Shanghai-based Junshi Biosciences has announced a partnership with Denmark’s LEO Pharma to distribute and commercialise the ...

The certification covers the company’s manufacturing facility for cephalosporin, carbapenem, and lyophilized injectable ...

Toripalimab, independently developed by Junshi Biosciences, is a monoclonal antibody targeting PD-1 for the treatment of multiple malignant tumors. To date, toripalimab has been approved for marketing ...

The UK government has been involved in a lot of shuttle diplomacy with the EU since Labour won the UK election Early in 2025, Prime Minister Sir Keir Starmer has been invited to an informal summit ...

Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...

X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and commercial milestone payments in addition to ...

Health Care Without Harm aims to transform global healthcare to minimize its environmental impact and promote sustainability ...

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...

The European pharma sector is on the brink of regulatory and operational updates with new papers from pharmaceutical ...

Indian pharmaceutical companies are projected to achieve a revenue ... Indian pharma companies have a substantial share in the prescription market in the US and EU. The largest number of FDA-approved ...

The extension to the marketing authorisation means paediatric patients aged up to 17 years with a confirmed diagnosis of ...

Credit: FatCamera via Shutterstock. The European Commission (EC) has extended the approval of Ultragenyx Pharmaceutical’s Evkeeza (evinacumab) to include children aged six months to less than five ...